JAMA Intern Med:PCI vs CABG对冠心病患者全因及特异性死亡率的影响

2020-10-13 MedSci原创 MedSci原创

与接受冠状动脉旁路移植术的患者相比,接受经皮冠状动脉介入治疗术后5年,冠心病患者的全因、心脏性和非心脏性死亡风险均较高

经皮冠状动脉介入治疗(PCI)和冠状动脉旁路移植术(CABG)对患者死亡率的影响是相关临床研究的主要评估内容,但以全因死亡率还是心源性死亡率作为研究终点存在争议。近日研究人员在随机临床试验(RCTs)中比较PCI或CABG治疗冠心病患者的全因死亡率和病因特异性死亡率差异。

本次研究为系统综述及荟萃分析,收集了MEDLINE(1946年至今)、Embase(1974年至今)和Cochrane图书馆(1992年至今)数据库数据,涉及PCI、药物洗脱或裸金属支架和CABG治疗冠心病的RCTs,报告了患者死亡率和/或病因特异性死亡率。排除了PCI介入性无支架血管成形术试验。研究的主要结果是全因和原因特异性(心脏和非心脏)死亡率。

总计23项试验纳入本次研究,包括13620例冠心病患者,其中6829例接受PCI,6791例接受CABG;男性占研究人群的39.9%-99.0%,平均年龄范围为60.0-71.0岁,平均随访5.3年。与CABG相比,PCI患者的全因(发病率比:1.17)死亡率、心脏(发病率比:1.24)死亡率和非心脏死亡率(发病率比:1.19)均较高。

研究认为,与接受冠状动脉旁路移植术的患者相比,接受经皮冠状动脉介入治疗术后5年,冠心病患者的全因、心脏性和非心脏性死亡风险均较高。

原始出处:

Mario Gaudino et al. Overall and Cause-Specific Mortality in Randomized Clinical Trials Comparing Percutaneous Interventions With Coronary Bypass Surgery A Meta-analysis. JAMA Intern Med. October 12, 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1899431, encodeId=92d2189943136, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Dec 03 00:37:07 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897459, encodeId=d0d089e459bc, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=148f5392162, createdName=ms2000001971593954, createdTime=Fri Nov 06 23:48:44 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447781, encodeId=e9e9144e78187, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Oct 15 10:37:07 CST 2020, time=2020-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610753, encodeId=9c3a1610e53a3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 15 10:37:07 CST 2020, time=2020-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036303, encodeId=870810363030d, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Tue Oct 13 22:37:07 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891842, encodeId=f3ba891842f5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3282551952, createdName=12543f43m99暂无昵称, createdTime=Tue Oct 13 19:58:46 CST 2020, time=2020-10-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1899431, encodeId=92d2189943136, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Dec 03 00:37:07 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897459, encodeId=d0d089e459bc, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=148f5392162, createdName=ms2000001971593954, createdTime=Fri Nov 06 23:48:44 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447781, encodeId=e9e9144e78187, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Oct 15 10:37:07 CST 2020, time=2020-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610753, encodeId=9c3a1610e53a3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 15 10:37:07 CST 2020, time=2020-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036303, encodeId=870810363030d, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Tue Oct 13 22:37:07 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891842, encodeId=f3ba891842f5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3282551952, createdName=12543f43m99暂无昵称, createdTime=Tue Oct 13 19:58:46 CST 2020, time=2020-10-13, status=1, ipAttribution=)]
    2020-11-06 ms2000001971593954

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1899431, encodeId=92d2189943136, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Dec 03 00:37:07 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897459, encodeId=d0d089e459bc, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=148f5392162, createdName=ms2000001971593954, createdTime=Fri Nov 06 23:48:44 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447781, encodeId=e9e9144e78187, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Oct 15 10:37:07 CST 2020, time=2020-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610753, encodeId=9c3a1610e53a3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 15 10:37:07 CST 2020, time=2020-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036303, encodeId=870810363030d, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Tue Oct 13 22:37:07 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891842, encodeId=f3ba891842f5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3282551952, createdName=12543f43m99暂无昵称, createdTime=Tue Oct 13 19:58:46 CST 2020, time=2020-10-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1899431, encodeId=92d2189943136, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Dec 03 00:37:07 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897459, encodeId=d0d089e459bc, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=148f5392162, createdName=ms2000001971593954, createdTime=Fri Nov 06 23:48:44 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447781, encodeId=e9e9144e78187, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Oct 15 10:37:07 CST 2020, time=2020-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610753, encodeId=9c3a1610e53a3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 15 10:37:07 CST 2020, time=2020-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036303, encodeId=870810363030d, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Tue Oct 13 22:37:07 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891842, encodeId=f3ba891842f5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3282551952, createdName=12543f43m99暂无昵称, createdTime=Tue Oct 13 19:58:46 CST 2020, time=2020-10-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1899431, encodeId=92d2189943136, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Dec 03 00:37:07 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897459, encodeId=d0d089e459bc, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=148f5392162, createdName=ms2000001971593954, createdTime=Fri Nov 06 23:48:44 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447781, encodeId=e9e9144e78187, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Oct 15 10:37:07 CST 2020, time=2020-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610753, encodeId=9c3a1610e53a3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 15 10:37:07 CST 2020, time=2020-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036303, encodeId=870810363030d, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Tue Oct 13 22:37:07 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891842, encodeId=f3ba891842f5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3282551952, createdName=12543f43m99暂无昵称, createdTime=Tue Oct 13 19:58:46 CST 2020, time=2020-10-13, status=1, ipAttribution=)]
    2020-10-13 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1899431, encodeId=92d2189943136, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Dec 03 00:37:07 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897459, encodeId=d0d089e459bc, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=148f5392162, createdName=ms2000001971593954, createdTime=Fri Nov 06 23:48:44 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447781, encodeId=e9e9144e78187, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Oct 15 10:37:07 CST 2020, time=2020-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610753, encodeId=9c3a1610e53a3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 15 10:37:07 CST 2020, time=2020-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036303, encodeId=870810363030d, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Tue Oct 13 22:37:07 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891842, encodeId=f3ba891842f5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3282551952, createdName=12543f43m99暂无昵称, createdTime=Tue Oct 13 19:58:46 CST 2020, time=2020-10-13, status=1, ipAttribution=)]
    2020-10-13 12543f43m99暂无昵称

    学习

    0

相关资讯

EXCEL研究5年结果公布,CABG和PCI孰优孰劣?

《新英格兰医学杂志》(NEJM)发表的一项名为EXCEL的临床试验,从去年9月在美国TCT年会初步公布5年随访结果,到10月欧洲EACTS年会公开辩论,再到12月BBC曝光所谓“隐匿的真相

JAMA Intern Med:PCI策略与急性心肌梗死和心源性休克患者不良预后

近年来急性心肌梗死和心源性休克患者接受多血管经皮冠状动脉介入治疗的比例逐年增加,但相比于主要梗死血管PCI,多血管PCI后患者的不良预后率也显著增加

Lancet:新冠肺炎疫情对英国急性冠状动脉综合征患者入院治疗率的影响

研究发现,新冠肺炎疫情期间,英国急性冠状动脉综合征患者入院治疗人数大幅减少,虽然到2020年5月底,这一数字已部分逆转,但在此期间入院人数的减少可能导致院外患者死亡和心肌梗死并发症风险增加

EuroIntervention:肥胖悖论——BMI的适度增加与PCI后患者生存率的改善相关

本研究旨在评估接受经皮血管重建术的冠状动脉疾病患者的体重指数(BMI)与结局之间的关系。

Circulation:经皮冠状动脉介入治疗置入药物洗脱支架后的双重抗血小板治疗时间

经皮冠状动脉介入治疗(PCI)置入药物洗脱支架(DES)后双抗血小板治疗(DAPT)的最佳持续时间仍不确定。近日,心血管领域权威杂志Circulation上发表了一篇研究文章,研究人员比较了 PCI置

Lancet:曲美他嗪对PCI后心绞痛患者预后的影响

心绞痛患者在成功接受经皮冠状动脉介入治疗后,服用曲美他嗪对心绞痛的复发或预后无显著改善作用